Questions Asked After Akorn’s Sudden Shutdown
US Representative Expresses ‘Deep Concerns’ As Company Ceases All Operations
Executive Summary
Akorn is facing questions after suddenly shutting down its operations and terminating its employees, with a chapter 7 bankruptcy filing on the cards. Answers are being sought over why the company did not provide advance warnings to employees given the precarious state of its finances.
You may also be interested in...
Akorn Sharpens Focus As It Divests Ophthalmic Brands
Akorn says it is concentrating its focus on “targeted avenues of growth” – including human generics and animal care – after divesting its branded ophthalmic portfolio to Théa Pharma.
Akorn Offloads Consumer Health For $230m
Akorn has announced a $230m all-cash deal to divest its consumer healthcare business to Prestige Consumer Healthcare. The transaction will allow Akorn – which recently went through bankruptcy proceedings – to invest in optimizing its prescription business.
Bankruptcy Court Gives Green Light To Akorn Sale
Just three years after Fresenius Kabi agreed a $4.75bn takeover of the US injectables specialist, Akorn has obtained approval from a US bankruptcy court for its sale to the company’s existing lenders, having filed for Chapter 11 bankruptcy earlier this year.